Erul, E.; Öksüz, N.E.; Akkus, E.; Tolunay, P.K.; Köksoy, E.B.; Yasar, H.A.
Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort. Medicina 2025, 61, 1960.
https://doi.org/10.3390/medicina61111960
AMA Style
Erul E, Öksüz NE, Akkus E, Tolunay PK, Köksoy EB, Yasar HA.
Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort. Medicina. 2025; 61(11):1960.
https://doi.org/10.3390/medicina61111960
Chicago/Turabian Style
Erul, Enes, Nejat Emre Öksüz, Erman Akkus, Pınar Kubilay Tolunay, Elif Berna Köksoy, and Hatime Arzu Yasar.
2025. "Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort" Medicina 61, no. 11: 1960.
https://doi.org/10.3390/medicina61111960
APA Style
Erul, E., Öksüz, N. E., Akkus, E., Tolunay, P. K., Köksoy, E. B., & Yasar, H. A.
(2025). Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort. Medicina, 61(11), 1960.
https://doi.org/10.3390/medicina61111960
